Abstract
Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 125-126 |
| Number of pages | 2 |
| Journal | Indian Journal of Pharmacology |
| Volume | 46 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Adverse drug reactions
- Bevacizumab
- Colorectal cancer
- Necrotizing fasciitis
Fingerprint
Dive into the research topics of 'Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver